3Nudel U, Zakut R, Shard M, et al. The nucleotide .sequence of the rat cytoplasmic β-actin gene. Nucleic acids research, 1983 ; 11 (6) 1759-1771.
4Bucala R, Vlassara H. Advanced glycosylation endprcxlucts in diabetic renal disease: clinical measurement, pathophysiological significance, and prospects for pharmacological inhibition. Blood Purif, 1995, 13:160-166.
5Brownlee M, Vlassara H, Kooney A, et al. Aminoguaridine prevents diabetes-induced arterial wall protein cross-linking. Science, 1986; 232:1629-1632.
6Kumaril, Umar S, Bannsal V, et al. Inhibition of diabetesassociated complications by nucleophilic compounds, Diabetes, 1991 ;40:1079-1084.
7Edelstein D, Brownlee M, Mechanistic studies of advanced glyeosylation endprcduct inhibition by aminogtuanidine. Diabetes, 1992 ; 41 : 26-29.
8Soulis-liparota T, cooper M, Papazoglou D, et al. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptezocin-indueed diabetic rat. Diabetes, 1991 ; 40(10) : 1322-1334.
9DY Shi, Schmidt AM, Anderson GM, et al. Enhanced cellular oxidant strexs by the interaction of advanced glycation end products with their receptors/binding proteins. J Bio Chem, 1994; 269(13) : 9989-9997.
10Wautier JL, Wautier MP, Schmidt AM, et al. Advanced glycation end products on the surface for diabetic erythrocyres bind to he vessel wall via a specific receptor inducing oxidant stress in the vasculature: A link between surface-associated AGEs and diabetic complications. Proc Natl Acad Sci,1994; 91:7742-7746.
